CJC-1295 + Ipamorelin (5mg/5mg) · Research brief
CJC-1295 No DAC: Research Speed Considerations
Short answer
For anyone sourcing this compound at volume, "speed" carries two meanings at once, and both belong in the buying decision. Pharmacologically, CJC-1295 without the Drug Affinity Complex is the short-acting form — the published literature on modified GRF (1-29) describes a brief circulating window, minutes rather than the multi-day profile attributed to DAC-conjugated versions.
CJC-1295 No DAC: Research Speed Considerations
For anyone sourcing this compound at volume, "speed" carries two meanings at once, and both belong in the buying decision. Pharmacologically, CJC-1295 without the Drug Affinity Complex is the short-acting form — the published literature on modified GRF (1-29) describes a brief circulating window, minutes rather than the multi-day profile attributed to DAC-conjugated versions. Operationally, that short window pushes speed downstream into everything else: how tightly a research protocol has to sample, how quickly lyophilized inventory turns over, and how fast a supplier can actually put a tested, documented batch on your receiving dock. Buyers who evaluate only one of those two meanings usually get surprised by the other.
All compounds discussed here are research-use-only materials. Nothing below is dosing, administration, or preparation guidance, and none of it describes use in people.
Why removing the DAC changes the clock
CJC-1295 is a modified fragment of growth hormone-releasing hormone. The DAC — Drug Affinity Complex — is a conjugated element designed to bind albumin in circulation, and research reports attribute the long-acting behavior of the DAC version to that binding. Strip the DAC away and what remains is the bare modified fragment, sometimes labeled modified GRF (1-29) in the literature. Studies indicate it clears quickly, which is the entire point of the variant: investigators studying pulsatile signaling generally want an agent that appears and disappears rather than one that sits in circulation for days.
That difference is not a quality gradient. Neither form is "better"; they answer different research questions. Short-acting analogs are used in work that examines transient receptor engagement and rapid downstream signaling in preclinical models. Long-acting conjugates suit designs where sustained exposure is the variable under study. A wholesale buyer stocking for a customer base of research institutions, labs, and resellers needs to understand that the two are not interchangeable SKUs, because a customer who orders the wrong one has a study design that no longer works.
This matters for catalog decisions. If your buyers are asking specifically for the no-DAC form, substituting the conjugated version to fill an out-of-stock line is not a neutral swap, and it will cost you the account. Carrying the specific form your customers request — clearly labeled, with the COA naming the exact sequence — is a basic commercial requirement, not a nicety.
How a short exposure window reshapes study design
When a compound clears fast, the experimental burden shifts toward timing. Sampling intervals compress. Assay windows narrow. Sequencing work that would be forgiving with a long-acting agent becomes unforgiving with a short-acting one, because the signal the investigator is chasing may exist only in a narrow slice of the timeline. Research groups working with short-half-life secretagogue analogs typically build far denser sampling schedules than groups working with sustained-exposure agents, and they plan their reagent supply around that density.
For a supplier, the practical consequence is consumption pattern. Research programs built on tight sampling burn through material in bursts. A lab may sit quiet for weeks and then consume a large block of vials in a single study run. Buyers who stock this category and model demand as smooth monthly draw tend to stock out at exactly the wrong moment, then discover their supplier's replenishment cycle is longer than their customer's study window.
There is also a documentation dimension. Fast-clearing compounds leave less room for ambiguity about what was in the vial. When results hinge on a short window, investigators want batch-specific analytical data — not a generic certificate for the product line, but the actual report for the lot they received. That expectation is rising across the research market, and it separates suppliers who publish verifiable lot documentation from those who do not.
Short-acting and long-acting analogs at a glance
| Consideration | Short-acting (no DAC) | DAC-conjugated |
|---|---|---|
| Circulating profile described in literature | Brief; reported in minutes | Extended; attributed to albumin binding |
| Typical research framing | Transient signaling, pulsatile study designs | Sustained-exposure study designs |
| Sampling demands on the investigator | Dense, tightly timed | More forgiving intervals |
| Consumption pattern for your inventory | Burst-driven, study-run dependent | Steadier, lower unit velocity |
| Substitution risk | High — not interchangeable with the DAC form | High — not interchangeable with the no-DAC form |
| Documentation buyers expect | Lot-specific COA, sequence confirmed | Lot-specific COA, sequence confirmed |
The row that costs money is the substitution row. Treat the two forms as distinct catalog lines with distinct reorder points, and label them that way for your own customers.
The supply-side meaning of speed
Speed on the procurement side is about the interval between recognizing a need and having tested material in hand. Several links in that chain are invisible until they fail.
Order-to-ship time. Ask any prospective supplier for their stated fulfillment window and whether it is measured from order placement or from payment clearance. Ask whether it changes for first orders, for larger quantities, or for compounds that are not held in domestic stock.
Domestic versus overseas fulfillment. A program that drop-ships from overseas can quote attractive unit pricing and then deliver on a timeline that makes the pricing irrelevant. Customs variability is the part nobody quotes. Domestic fulfillment is a materially different operating model, and it is worth asking directly where product physically ships from.
Testing turnaround. If a supplier tests each batch — and they should — that testing sits in the timeline. The question is whether they hold tested stock ready to ship or whether your order triggers the testing cycle. The first model ships fast; the second does not.
Restock cadence. For a burst-consumption compound, the number that matters is not lead time on a single order but how quickly the supplier can backfill after they sell through. A supplier with thin depth will quote you a good lead time on the order that empties their shelf and a bad one on everything after.
Costs and minimums in this category vary widely by volume, compound, and program structure, so treat any quoted figure as specific to that supplier rather than an industry norm. What you can compare cleanly is transparency: whether pricing tiers are stated plainly, whether minimums are disclosed before you apply, and whether anything material is withheld until you are already in a sales conversation.
What to verify before you commit to any supplier
The verification list below applies to this compound and to everything else in a research catalog.
- Purity method and threshold. HPLC purity should be stated with a number and backed by the chromatogram, not asserted as a marketing adjective.
- Identity confirmation. Mass spectrometry confirming the sequence matters more for a short-acting variant than most buyers realize, because the no-DAC form is defined by what was left off.
- Full-panel batch testing. Purity and identity alone are an incomplete picture. Ask what else is screened per lot and whether every lot is screened or only a sample.
- COA accessibility. Lot-specific certificates should be verifiable by you, without a request form and without a fee. Suppliers who sell COAs separately, or who send a certificate that does not match your lot number, have told you something.
- Labeling discipline. Research-use-only labeling, correct compound naming, and lot traceability on the vial itself.
- Pricing structure in writing. Tiers, minimums, and how volume changes the unit price — before you apply, not after.
- Fulfillment origin and stated ship window.
One note on what a supplier should decline to give you: dosing, reconstitution, or preparation instructions. A wholesale partner that volunteers administration guidance for a research-use-only compound is creating a liability for both of you. Real Peptides does not provide dosing or preparation guidance, because these are research-use-only materials. The furthest legitimate education goes is the concentration framework itself — milligrams per milliliter as a unit of measure — and the investigator's own protocol governs everything beyond that.
Regulatory questions sit in the same category. Whether your business may stock, resell, or distribute research compounds in your jurisdiction depends on your entity type, your licensing posture, and rules that differ from state to state. Those are questions for your attorney and your state board, not for a supplier's blog. This article is informational and is not legal advice.
What Real Peptides does differently
Real Peptides operates a Wholesale Partner Program built for businesses that need the verification items above answered before the first order, not after.
Every compound is tested to a 99%+ HPLC purity standard, with seven-panel batch testing applied per lot rather than to a representative sample. Certificates of analysis are publicly verifiable — a prospective partner can pull the lab results and check them independently, without a paywall, a request queue, or a sales call standing between them and the data. For a compound like the short-acting CJC-1295 variant, where identity confirmation is the whole question, that open documentation is the difference between trusting a claim and checking one.
Fulfillment is domestic, with orders shipping in five to seven days. That removes the customs variability that makes overseas sourcing hard to plan around, which matters most for buyers serving research customers whose consumption arrives in bursts.
The Wholesale Partner Program uses a three-step application: submit your business information, complete verification review, and receive access to partner pricing tiers. Pricing structure is disclosed to approved partners directly rather than being withheld as a negotiating lever, which is the practice this program was built to avoid.
Where qualified buyers go from here
If you are stocking short-acting research compounds and the verification list above is the standard you hold suppliers to, the Wholesale Partner Program application is the next step. Bring your business details and your questions about tiers, minimums, and batch documentation — the review step exists so both sides know what they are agreeing to before inventory moves.
Buyers researching this category can review the CJC-1295 No DAC 10mg listing alongside related compounds such as Ipamorelin 10mg and Tesamorelin 10mg, or browse the broader growth factor and tissue signaling research and popular peptides collections to see how catalog depth lines up with what your customers order.
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA